LOGIN IN
REGISTER
PRODUCTS
More than 5000 active chemicals with high quality for research!

Email sales@dcchemicals.com

        order@dcchemicals.com

        info@dcchemicals.com


Phone:  +86-21-58447131

Fax   +86-21-61642470

Trabectedin
DC10611  (CAS:114899-77-3)
(Based on popularity)
Size Price Availability
5mg USD 1900 in stock
10mg USD 2800 in stock
25mg USD 3700 in stock
We match the best price and quality on market.
 
 
Email: order@dcchemicals.com
Tel: +86-21-58447131
Fax:+86-21-61642470
Fields of Application :
Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo.
CAS Number: 114899-77-3
Purity:

>99%

Molecular Weight: 761.91
Molecular Formula: C39H43N3O11S
Quality Control: HPLCNMR LC/MS(Please contact us to get the QC report)
Synonyms: Ecteinascidin 743; ET-743; Ecteinascidin
Chemical Name:
Storage: 2 years -20C Powder, 2 weeks4C in DMSO,6 months-80C in DMSO
Note: Products for research use only, not for human use
Description:
Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo. IC50 Value: 0.1-3.7 nM (breast cancer cell lines) Target: Apoptosis inducer; Anticancer in vitro: Trabectedin induced cytotoxicity and apoptosis in both breast cancer cells in a time and concentration-dependent manner. The expression levels of the death receptor pathway molecules, TRAIL-R1/DR4, TRAIL-R2/DR5, FAS/TNFRSF6, TNF RI/TNFRSF1A, and FADD were significantly increased by 2.6-, 3.1-, 1.7-, 11.2- and 4.0-fold by trabectedin treatment in MCF-7 cells. However, in MDA-MB-453 cells, the mitochondrial pathway related pro-apoptotic proteins Bax, Bad, Cytochrome c, Smac/DIABLO, and Cleaved Caspase-3 expressions were induced by 4.2-, 3.6-, 4.8-, 4.5-, and 4.4-fold, and the expression levels of anti-apoptotic proteins Bcl-2 and Bcl-XL were reduced by 4.8- and 5.2-fold in MDA-MB-453 cells . In vitro treatment with noncytotoxic concentrations of trabectedin selectively inhibited the production of CCL2, CXCL8, IL-6, VEGF, and PTX3 by MLS primary tumor cultures and/or cell lines . in vivo: A xenograft mouse model of human MLS showed marked reduction of CCL2, CXCL8, CD68+ infiltrating macrophages, CD31+ tumor vessels, and partial decrease of PTX3 after trabectedin treatment . The MTD of trabectedin was 700 microg/m(2) due to dose-limiting neutropaenia and the RDs in the previously treated/untreated patients were 500 and 600 microg/m(2), respectively. Most common toxicities were nausea/vomiting (67%), asthenia/fatigue (55%) and reversible ASAT/ALAT elevation (51%) . Toxicity: Most common toxicities were nausea/vomiting (67%), asthenia/fatigue (55%) and reversible ASAT/ALAT elevation (51%) . Clinical trial: A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies.
References:
O[C@@H]1N2[C@H]([C@H]3C4=C(O)C(OC)=C(C)C=C4C[C@@H]1N3C)[C@@](SC[C@@]5(NCC6)C7=C6C=C(O)C(OC)=C7)([H])C8=C(OC(C)=O)C(C)=C9C(OCO9)=C8[C@@H]2COC5=O
About us Products Services ordering sitemap
Phone: +86-21-58447131Fax: +86-21-61642470
ADDRoom 610, Building 15, Jinxiang Rd 201, Pudong,Shanghai, China
CopyRight-2010-2013 DC Chemicals All Rights Reserved